


RESEARCH ARTICLE

The importance of conserved amino acids in heme-based globin-coupled diguanylate cyclases

Xuehua Wan^{1,2*}, Jennifer A. Saito^{1,2}, James S. Newhouse², Shaobin Hou^{1,2}, Maqsudul Alam^{1,2†}

1 Department of Microbiology, University of Hawaii, Honolulu, Hawaii, United States of America, **2** Advanced Studies in Genomics, Proteomics and Bioinformatics, University of Hawaii, Honolulu, Hawaii, United States of America

† Deceased.
* xuehua@hawaii.edu



OPEN ACCESS

Citation: Wan X, Saito JA, Newhouse JS, Hou S, Alam M (2017) The importance of conserved amino acids in heme-based globin-coupled diguanylate cyclases. PLoS ONE 12(8): e0182782. <https://doi.org/10.1371/journal.pone.0182782>

Editor: Shihui Yang, National Renewable Energy Laboratory, UNITED STATES

Received: May 15, 2017

Accepted: July 24, 2017

Published: August 8, 2017

Copyright: © 2017 Wan et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the National Science Foundation (grant no. MCB0446431) (MA). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Globin-coupled diguanylate cyclases contain globin, middle, and diguanylate cyclase domains that sense O₂ to synthesize c-di-GMP and regulate bacterial motility, biofilm formation, and virulence. However, relatively few studies have extensively examined the roles of individual residues and domains of globin-coupled diguanylate cyclases, which can shed light on their signaling mechanisms and provide drug targets. Here, we report the critical residues of two globin-coupled diguanylate cyclases, *EcGReg* from *Escherichia coli* and *BpeGReg* from *Bordetella pertussis*, and show that their diguanylate cyclase activity requires an intact globin domain. In the distal heme pocket of the globin domain, residues Phe42, Tyr43, Ala68 (*EcGReg*)/Ser68 (*BpeGReg*), and Met69 are required to maintain full diguanylate cyclase activity. The highly conserved amino acids His223/His225 and Lys224/Lys226 in the middle domain of *EcGReg*/*BpeGReg* are essential to diguanylate cyclase activity. We also identified sixteen important residues (Leu300, Arg306, Asp333, Phe337, Lys338, Asn341, Asp342, Asp350, Leu353, Asp368, Arg372, Gly374, Gly375, Asp376, Glu377, and Phe378) in the active site and inhibitory site of the diguanylate cyclase domain of *EcGReg*. Moreover, *BpeGReg*₂₆₆ (residues 1–266) and *BpeGReg*₂₉₆ (residues 1–296), which only contain the globin and middle domains, can inhibit bacterial motility. Our findings suggest that the distal residues of the globin domain affect diguanylate cyclase activity and that *BpeGReg* may interact with other c-di-GMP-metabolizing proteins to form mixed signaling teams.

Introduction

Globin-coupled diguanylate cyclases (GCDCs) form a subfamily of globin-coupled sensors (GCS) that are heme-binding sensors linked to variable signaling domains [1–5]. The N-terminal globin domains of GCDCs consist of eight alpha helices and display a myoglobin-like topology [6, 7]. The ferrous ion centered in the heme reversely binds O₂, and distal residues facilitate O₂ migration and stabilization in the hydrophobic heme pocket [6, 8–10]. In the C-

terminal diguanylate cyclase (DGC) domains of GCDCs, the highly conserved GGD/EEF (Gly-Gly-Asp/Glu-Glu-Phe) motif serves as the active site to synthesize the second messenger bis-(3'-5')-cyclic diguanosine monophosphate (c-di-GMP) [6, 8].

C-di-GMP-dependent signaling pathways regulate diverse cellular functions including motility, biofilm formation, virulence, differentiation, and the cell cycle [11]. Various c-di-GMP receptors have been identified in bacteria and the mammalian innate immune system [12–20]. C-di-GMP is synthesized by DGCs (including GCDCs) containing a GGDEF domain and degraded by phosphodiesterases (PDEs) with either an EAL or HD-GYP domain [11]. Multiple DGCs and PDEs are found in most bacteria and are often associated with sensory or regulatory domains that allow them to modulate their activities in response to internal and environmental stimuli [11]. Studies on how DGCs and PDEs sense environmental signals to regulate c-di-GMP levels will shed light on the mechanisms of bacterial behavior and provide potential drug targets to attenuate the virulence of pathogens.

Various GCDCs have been characterized from *Escherichia coli*, *Bordetella pertussis*, *Azotobacter vinelandii*, *Desulfotalea psychrophila*, *Shewanella putrefaciens*, and *Pectobacterium carotovorum* [6, 8–10, 21–23]. Two GCDCs, *EcGReg* (also named *DosC*) from *E. coli* and *BpeGReg* from the whooping cough pathogen *B. pertussis*, can sense O₂ to regulate c-di-GMP synthesis [6, 8]. They differ in respect of O₂ affinity and cooperative PDEs [6, 8, 24]. *EcGReg* and *EcDosp* (EAL type) couple to control c-di-GMP homeostasis, whereas *BpeGReg* may cooperate with *BpeRpfG* (HD-GYP type) [8, 24]. To address related questions on how globins regulate DGC activity, here we report the critical residues identified in the three domains of GCDCs and that GCDCs require an intact globin domain for their enzyme activities. We examined Phe42, Tyr43, Ala68 (*EcGReg*)/Ser68 (*BpeGReg*), and Met69, which are in the distal heme pocket of the globin domain. We also tested the highly conserved amino acids His223/His225 and Lys224/Lys226 in the middle domain of *EcGReg* and *BpeGReg*. In addition, we used *EcGReg* as a model to examine sixteen conserved residues in the active site and inhibitory site of the DGC domains. We propose that distal globin residues facilitate O₂ binding to regulate DGC activity and *BpeGReg* may interact with other DGCs to form mixed signaling teams.

Materials and methods

Sequence alignment and visualization of predicted critical residues

Protein sequences were aligned using EBI-MAFFT [25, 26]. The alignment was visualized by using EBI-MView [26, 27]. The homology model of *BpeGReg* was created previously [6]. Visualization of the locations of the critical residues was carried out using UCSF Chimera [28].

Plasmid construction

The *ecGReg* (GenBank accession no. NP_416007) and *bpeGReg* (GenBank accession no. NP_882025) genes were cloned into the pTrc99A vector (primers listed in Table A in S1 File). The truncated versions of these genes were also cloned into the pTrc99A vector (primers listed in Tables B and C in S1 File).

The plasmids containing the full-length genes were used as templates for the QuickChange site-directed mutagenesis protocol (Stratagene). Briefly, *PfuTurbo* DNA polymerase (Stratagene) and the primers listed in Tables B and C in S1 File were used for polymerase chain reactions (PCR). Thermal cycling was carried out with 12 cycles as follows: 94°C for 30 seconds, 55°C for 30 seconds, and 68°C for 12 minutes, with a final extension at 68°C for 7 minutes. One microliter of *DpnI* (10 U/μl, Promega) was then added to digest the methylated parental DNA template at 37°C for 1 hour. The mutated plasmids were transformed into *E. coli* TOP10

cells (Invitrogen). The coding regions of the isolated plasmids were verified by Sanger sequencing on ABI 3730xl DNA analyzer.

For protein expression and purification, full-length and truncated *BpeGReg* proteins were engineered with an N-terminal hexahistidine tag by PCR. Primers are listed in Table D in [S1 File](#). The PCR products were cloned into the pCR4Blunt-TOPO vector (Invitrogen) and then subcloned into the pET-3a expression vector (Novagen).

The laboratory protocol of the molecular cloning has been deposited in protocols.io (DOI: <http://dx.doi.org/10.17504/protocols.io.ijxcccpn>).

Phenotypic assays

Plasmids were transformed into *Salmonella typhimurium* ATCC 14028 by electroporation and maintained in LB broth or plates with ampicillin (100 µg/ml) at 37°C. For biofilm formation, cells were grown on LB without salt plates containing Congo red (40 µg/ml) for 40 hours at 37°C. Swimming motility was assayed on 0.3% agar plates (1% tryptone, 0.5% NaCl, 1 µM thiamine) at 28°C for 6 hours. Due to leaky expression of the pTrc99A vector, isopropyl β-D-thiogalactopyranoside (IPTG) was not used to induce protein expression during these assays.

Overexpression, purification and absorption spectra

His-tagged *BpeGReg*, *BpeGReg*₁₅₅, *BpeGReg*₂₆₆, and *BpeGReg*₂₉₆ were overexpressed in *E. coli* Rosetta2(DE3)pLysS cells for 6–8 h at room temperature. Protein expression was induced with 0.05 mM isopropyl-β-D-thiogalactopyranoside. Proteins were purified by Co²⁺ affinity chromatography according to Piatibratov et al. [29]. The detailed protocol has been deposited in protocols.io (DOI: <http://dx.doi.org/10.17504/protocols.io.ikhcct6>). Spectra were measured using a Cary 1E UV-Visible spectrophotometer (Varian).

Results and discussion

Prediction of critical residues of globin-coupled diguanylate cyclases

The open reading frames of *ecGReg* and *bpeGReg* encode multidomain proteins containing 460 and 475 amino acids, respectively (Fig 1A). The region linking the N-terminal globin domain and C-terminal DGC domain could not be classified but is highly conserved in many GCDCs, including *EcGReg* and *BpeGReg* [3]. We refer to this region as the middle domain (Fig 1A). Fig 1B shows the protein sequence alignment of *EcGReg*, *BpeGReg*, and other GCDCs with the same domain architecture. We predicted a series of residues in the globin, middle, and DGC domains of *EcGReg* and *BpeGReg* that may affect their enzymatic activities, based on amino acid sequence alignment and the homology model of *BpeGReg* [6]. The crystal structure of *EcGReg* [7] was not available at the time this study was performed, so it was only used for subsequently visualizing the positions of the residues we tested rather than aiding our predictions (Fig 2).

In the *EcGReg* globin domain, the distal residue Tyr43 stabilizes O₂ to ferrous ion [10]. Our unpublished data suggests a similar role for Tyr43 in *BpeGReg*. We selected Tyr43 and three other residues in the distal heme pocket of both proteins for site-directed mutagenesis. In the middle domain, *BpeGReg* His225 was examined previously [6]. Here we selected His223 in *EcGReg* and nearby conserved residues Lys224 (*EcGReg*)/Lys226 (*BpeGReg*) for mutagenesis. To analyze the conserved residues in the DGC domain, we used *EcGReg* as a model and selected 16 residues in the active and inhibitory sites.

Mutated proteins were expressed in *Salmonella typhimurium* ATCC 14028 to examine their *in vivo* DGC activities by rdar (red, dry, and rough) formation and motility assays (Figs 3–6,




Fig 1. Two globin-coupled diguanylate cyclases consist of three domains. (A) Domain structures of *EcGReg* and *BpeGReg*. BLASTP searches against the non-redundant protein sequences database at the National Center for Biotechnology Information showed that *EcGReg* residues 5–153 represent a globin sensor domain and residues 268–458 represent a DGC domain, while *BpeGReg* residues 5–155 and residues 297–457 represent a globin sensor domain and a DGC domain, respectively. (B) Amino acid sequence alignment of five globin-coupled diguanylate cyclases: *EcGReg*, *BpeGReg*, *AvGReg* (*Azotobacter vinelandii*), *SpGReg* (*Shewanella putrefaciens*), and *PccGReg* (*Pectobacterium carotovorum*). The sequence order is based on the alignment. The residues highlighted in red are highly conserved and discussed in this work. The residues highlighted in blue are not highly conserved and discussed in this work. The line colors indicate the globin (orange), middle (green), and DGC (blue) domains.

<https://doi.org/10.1371/journal.pone.0182782.g001>




Fig 2. Positions of predicted critical amino acids in the crystal structure of *EcGReg/DosC*. (A) Crystal structure of the globin domain of *EcGReg/DosC* (pdb: 4zvb, ferrous form) shows the locations of the critical residues in the heme pocket. H98 is the proximal histidine which binds the heme. The side chains of F42, Y43, and M69 surround the heme center. The side chain of A68 points away from the heme center. (B) Crystal structure of the middle domain of *EcGReg/DosC* (pdb: 4zvc, form I) shows the locations of critical residues H223 and K224. (C) Crystal structure of the DGC domain of *EcGReg/DosC* (pdb: 4zvf, GTPaS-bound) shows the locations of mutated residues in this work.

<https://doi.org/10.1371/journal.pone.0182782.g002>




Fig 3. Rdar morphotype development of *EcGReg* mutants on Congo red agar plates. (A) Rdar morphotypes of *EcGReg* globin domain mutants. (B) Rdar morphotypes of *EcGReg* middle domain mutants. (C) Rdar morphotypes of *EcGReg* DGC domain mutants. (D) Rdar morphotypes of truncated *EcGReg* proteins.

<https://doi.org/10.1371/journal.pone.0182782.g003>

Tables 1 and 2). High levels of intracellular c-di-GMP can inhibit motility, increase the production of exopolysaccharides (EPS) (e.g., cellulose) and adhesion factors (e.g., curli fimbriae), and enhance biofilm formation [30]. *S. typhimurium* develops an rdar morphotype on Congo red agar plates at 28°C but not at 37°C, indicating the expression of cellulose and curli fimbriae [31, 32]. At 37°C, the temperature regulation of rdar morphotype development can be overcome by overexpression of the DGC AdrA as well as heterologous expression of other DGCs such as *EcGReg* and *BpeGReg* [6, 30, 33].

Phe42, Tyr43, Ala68/Ser68 and Met69 in the globin distal heme pockets of *EcGReg* and *BpeGReg* are required for DGC activity

In the N-terminal globin domains, we selected residues because they were located near the distal heme pocket, affecting the orientation and migration of ligands. Expression of the *EcGReg* distal residue mutants, F42A, Y43A, A68T, and M69A, produced the rdar morphotype but failed to inhibit *S. typhimurium* motility (Figs 3A and 4A). Similar results were also observed for the *BpeGReg* mutants F42A and M69A (Figs 5A and 6A). On the other hand, the *BpeGReg* Y43A mutation severely impaired rdar development but did not affect the ability to inhibit motility (Figs 5A and 6A). Only the *BpeGReg* S68A mutant could neither confer the rdar morphotype nor inhibit motility (Figs 5A and 6A). These results indicate that residues in the heme pocket of the globin domain are required for *EcGReg* and *BpeGReg* to be fully active. Particularly, in *BpeGReg*, the hydroxyl group of Ser68 is required for full protein function.




Fig 4. Swimming motility of *EcGReg* mutants on 0.3% tryptone agar plates. (A) Swimming motility of *EcGReg* globin domain mutants. (B) Swimming motility of *EcGReg* middle domain mutants. (C) Swimming motility of *EcGReg* DGC domain mutants. (D) Swimming motility of truncated *EcGReg* proteins.

<https://doi.org/10.1371/journal.pone.0182782.g004>

His223/His225 and Lys224/Lys226 in the middle domains of *EcGReg* and *BpeGReg* are required for DGC activity

We previously demonstrated that *BpeGReg* could be inactivated by an H225A mutation in the middle domain, as no detectable *c*-di-GMP was produced *in vitro* and no *c*-di-GMP-dependent




Fig 5. Rdar morphotype development of *BpeGReg* mutants on Congo red agar plates. (A) Rdar morphotypes of pTrc99A vector control, *BpeGReg*, and *BpeGReg* globin domain mutants. (B) Rdar morphotypes of *BpeGReg* middle domain mutant. (C) Rdar morphotypes of truncated *BpeGReg* proteins.

<https://doi.org/10.1371/journal.pone.0182782.g005>




Fig 6. Swimming motility of *BpeGReg* mutants on 0.3% tryptone agar plates. (A) Swimming motility of pTrc99A vector control, *BpeGReg*, and *BpeGReg* globin domain mutants. (B) Swimming motility of *BpeGReg* middle domain mutant. (C) Swimming motility of truncated *BpeGReg* proteins.

<https://doi.org/10.1371/journal.pone.0182782.g006>

physiological effects were observed when expressed in *S. typhimurium* [6]. When the corresponding residue in *EcGReg* was mutated (H223A), this protein was also unable to induce the rdar morphotype or inhibit motility in *S. typhimurium* (Figs 3B and 4B). Mutation of another highly conserved residue, K224A (*EcGReg*)/K226A (*BpeGReg*), led to inactive phenotypes as well (Figs 3B–6B). Taken together, these results suggest an essential role of the middle domain for DGC activation. *EcGReg* His223 and Lys224 locate in a π -helix (residues 221–225) that constitutes the middle region of the α -helix B (residues 216–228) of the middle domain [7]. Although the α -helices-associated π -helices are overlooked and rarely annotated, they are present in ~15% of all proteins and tend to be associated with protein function, e.g. peristaltic-like shifts to extend the binding cavity of a substrate [34]. In the homodimer structure of the *EcGReg* middle domain (Fig 2B) [7], the side chains of His223 and Lys224 point towards the surrounding environment, contributing to the positive charges on the protein surface. Charged side chains on protein surfaces may play roles in allosteric regulation, protein-protein interaction, or folding/stability of protein. Further investigation will help us to understand the specific roles of the middle domain and the conserved π -helix of GCDCs.

Critical residues in the A-site and I-site of the DGC domain are required for enzyme activity

DGCs function as homodimers, with the two monomers forming the active site (A-site) at the dimer interface [35, 36]. The signature GG(D/E)EF motif constitutes part of the A-site, and several studies have suggested that absolute conservation of all five residues in this motif is required for catalysis [37, 38]. However, the first residue of the GG(D/E)EF motif appears to be flexible to substitutions in some DGCs. A DGC from *Pectobacterium atrosepticum* was observed to be active with Gly, Ser, or Ala in the first position, while a DGC from *Vibrio cholerae* was active with Gly, Ala, Met, or His [39, 40]. Using *EcGReg* as a model, we wanted to determine which residues of the GGDEF motif were essential for its catalytic function. We therefore mutated each residue of the GGDEF motif to Ala (G374A, G375A, D376A, E377A,

and F378A). All of these mutants failed in conferring the rdar morphotype or inhibiting motility in *S. typhimurium* (Figs 3C and 4C), indicating that the canonical GGDEF motif is required for the DGC activity of *EcGReg*. We further examined the roles of other residues within the A-site. Six mutations (R306A, D333A, F337A, D342A, D350A, and L353A) resulted in a lack of *in vivo* function (Figs 3C and 4C). Six other mutants retained partial function: cells harboring the L300A and K338A mutants formed a partial rdar morphotype (Fig 3C), while the L300D, N341A, L353D, and R372A mutants were able to inhibit or partially inhibit motility (Fig 4C). These results highlight the requirement of additional A-site residues for DGC activity, besides those of the GGDEF motif. Many of the residues (Asp333, Phe337, Lys338, Asn341, and Asp350) directly interact with either the substrate or metal ions in the A-site [7]. The other residues may help maintain the functional structure of the DGC domain.

An inhibitory site (I-site), consisting of an RXXD motif, is found in DGC domains, including those of *EcGReg* and *BpeGReg* [41]. The I-site is located five residues upstream of the GG (D/E)EF motif (Fig 1B). Feedback inhibition occurs when a c-di-GMP dimer binds to this allosteric site, thus decreasing DGC activity [35, 41]. We tested the effect of mutating the conserved Asp in the R₃₆₅XXD₃₆₈ motif of *EcGReg*. The D368A and D368K variants both lacked the ability to produce the rdar morphotype or inhibit motility in *S. typhimurium* (Figs 3C and 4C). This is consistent with the findings of Kitanishi *et al.* [10], who observed that *EcGReg* D368A did not have biofilm formation activity when expressed in *E. coli*. Furthermore, Burns *et al.* [42] found that mutation of the first Arg in the *BpeGReg* I-site (R364A) affected oligomerization and decreased catalytic activity, leading to the conclusion that the I-site plays a role in controlling the conformation/dynamics of DGC domains, in addition to product inhibition.

The mutations characterized in this study can be classified into three groups: 1) mutants that could no longer confer the rdar morphotype or inhibit motility; 2) mutants that could confer the rdar morphotype but not inhibit motility; and 3) mutants that could inhibit motility but not confer the rdar morphotype (Tables 1 and 2). We conclude that the group 1 mutants, which are mainly located within the middle and DGC domains, include the most crucial residues required for DGC activity. The group 2 and 3 mutants are found in the globin and DGC domains. Particularly, the globin distal residue mutants Y43A are classified into different groups (*EcGReg* in group 2 versus *BpeGReg* in group 3). The differential effects of the group 2 and 3 mutants on rdar formation and motility could be due to signaling specificity. Rdar formation and motility inhibition involve a number of processes that are regulated at multiple levels, and particular DGCs and/or PDEs are often attributed to regulating specific processes [11]. The molecular mechanisms by which *EcGReg* and *BpeGReg* exert their specificities are not yet clearly understood. We presume that the group 2 and 3 mutations led to decreased c-di-GMP production, resulting in threshold levels sufficient for activating one phenotype over the other. This could involve c-di-GMP receptors with different binding affinities [43]. However, we cannot exclude the possibility that proximity to the appropriate targets was disrupted, as some of the mutations may have affected localization of the GCDC proteins in the cell or their association into protein complexes. It was shown that *EcGReg*, along with *Ec* DosP, associates with PNPase in a ribonucleoprotein complex to regulate RNA turnover [15], but it is unknown how this may be connected to biofilm formation or motility.

The biofilm formation (rdar) activities of a few *EcGReg* mutant variants have been previously evaluated in *E. coli* [10, 44], and the results were, for the most part, in agreement with what we observed for similar mutant proteins expressed in *S. typhimurium*. However, there was one discrepancy. While the H223A mutant displayed a wild-type phenotype in *E. coli* [10], our result indicated that the activity of the mutant was impaired. Differences in the c-di-GMP signaling networks of *E. coli* and *S. typhimurium* may account for the different phenotypic outcomes [45]. Contributions of species-specific DGCs/PDEs, interactions with distinct sets of

Table 1. Summary of phenotypes of *S. typhimurium* expressing *EcGReg* mutants.

Residue	Mutant	RDAR	Motility inhibition	Group
Globin domain				
F42	A	+	-	2
Y43	A	+	-	2
A68	T	partial	-	2
M69	A	+	-	2
Middle domain				
H223	A	-	-	1
K224	A	-	-	1
DGC domain				
L300	A	partial	-	2
	D	-	+	3
R306	A	-	-	1
D333	A	-	-	1
F337	A	-	-	1
K338	A	partial	-	2
N341	A	-	partial	3
D342	A	-	-	1
D350	A	-	-	1
L353	A	-	-	1
	D	-	+	3
D368	A	-	-	1
	K	-	-	1
R372	A	-	+	3
G374	A	-	-	1
G375	A	-	-	1
D376	A	-	-	1
E377	A	-	-	1
F378	A	-	-	1

<https://doi.org/10.1371/journal.pone.0182782.t001>

proteins, or differences in the c-di-GMP thresholds needed to elicit a phenotypic response are among the possible factors that could lead to the variable effects seen in these organisms.

S. typhimurium expressing individual domains of *BpeGReg* and *EcGReg* cannot form the full rdar morphotype, while *BpeGReg*₂₆₆ and *BpeGReg*₂₉₆ can inhibit motility

Individual DGC domains have been shown to possess low-level enzymatic activity *in vitro*, which is several orders of magnitude lower than that of the full-length proteins [46]. A

Table 2. Summary of phenotypes of *S. typhimurium* expressing *BpeGReg* mutants.

Residue	Mutant	RDAR	Motility inhibition	Group
Globin domain				
F42	A	+	-	2
Y43	A	partial	+	3
S68	A	-	-	1
M69	A	+	-	2
Middle domain				
K226	A	-	-	1

<https://doi.org/10.1371/journal.pone.0182782.t002>

construct containing the middle and DGC domains of *EcGReg* (residues 173–460) exhibited four-fold less activity than the full-length protein, whereas the DGC domain alone (residues 297–460) did not have any detectable activity due to it being monomeric in solution [7]. In order to assess whether truncated forms of *EcGReg* and *BpeGReg* have DGC activity *in vivo*, we tested the functions of various constructs in *S. typhimurium* (Fig 7). We used *EcGReg* as a model to examine whether it could maintain its function when the globin domain was gradually truncated. All of the *EcGReg* truncated proteins could not confer a full rdar morphotype (Fig 3D), and were unable to inhibit motility as well (Fig 4D). We also tested the individual or combined domains of *BpeGReg*. Intriguingly, two of the *BpeGReg* constructs, *BpeGReg*₂₆₆ and *BpeGReg*₂₉₆ (residues 1–266 and 1–296), which only contain the globin and middle domains, were able to inhibit motility (Fig 6C). Compared to wild-type *BpeGReg*, the absorption spectra of *BpeGReg*₁₅₅, *BpeGReg*₂₆₆ and *BpeGReg*₂₉₆ showed that they were able to bind heme (Fig A in S1 File), indicating that the heme-based globin was present. The presence of the globin




Fig 7. Schematic diagram of truncated *EcGReg* (A) and *BpeGReg* (B).

<https://doi.org/10.1371/journal.pone.0182782.g007>

domain alone (*BpeGReg*₁₅₅), however, was not sufficient for eliciting a physiological response. Our data suggest that both the heme-based globin and middle domain are required for signaling and they may interact with other DGCs to form signaling clusters.

Our analysis of the truncated proteins suggests that the complete structures of *EcGReg* and *BpeGReg* are required for full DGC activity. Previous studies have demonstrated that the cyclase activity of GCDCs is regulated by O₂ binding to the globin sensor domain [6, 8, 21–23], so it is not surprising that the presence of this domain would be necessary for optimal function. However, it is unexpected to find that expression of two *BpeGReg* constructs lacking the DGC domain resulted in motility inhibition. As these proteins did not have the ability to synthesize c-di-GMP, we postulate that the globin and middle domains of *BpeGReg* may be able to interact with other DGCs, PDEs, or effector proteins to coordinate c-di-GMP signaling. Thus, the function of the truncated *BpeGReg* proteins may be partially rescued by its partners in mixed signaling teams. There is growing evidence for the involvement of protein-protein interactions in regulating c-di-GMP networks. For example, *EcGReg* forms a complex with the PDE DosP [8]; the stand-alone NO sensor H-NOX binds to HaCE, a dual-functioning DGC and PDE in *Shewanella woodyi* [47, 48]; and the DGC GcbC associates with its target receptor LapD in *Pseudomonas fluorescens* [49, 50].

Conclusion

Characterization of *EcGReg* and *BpeGReg* will provide general insights into the structure and function of GCSs. Here we provided evidence that residues Phe42, Tyr43, Ala68/Ser68 and Met69 in the distal heme pockets of *EcGReg* and *BpeGReg* could affect C-terminal DGC activity. His223/His225 and Lys224/Lys226 in the middle domains of *EcGReg* and *BpeGReg* were also required, and a number of critical residues in the A-site and I-site of the *EcGReg* DGC domain were identified. In addition, the full globin fold is required for GCDC activity. We further hypothesize that *BpeGReg*, via its globin and middle domains, may be able to form clusters with other c-di-GMP-metabolizing proteins. This may shed light on the functions of other globins, especially those single-domain proteins with unknown functions.

Supporting information

S1 File. Table A. Primers used for cloning *EcGReg* and *BpeGReg* in pTrc99A. Table B. Primers used for the construction of *EcGReg* mutants and truncated *EcGReg*. Table C. Primers used for the construction of *BpeGReg* mutants and truncated *BpeGReg*. Table D. Primers used for expression of truncated *BpeGReg* in pET-3a. Figure A. Absorption spectra of truncated *BpeGReg* proteins. a) Wild-type *BpeGReg* (solid red line) showed heme-bound absorption spectra. b) *BpeGReg*₁₅₅, *BpeGReg*₂₆₆, and *BpeGReg*₂₉₆ showed heme-bound absorption spectra, similar to that of wild-type *BpeGReg*. (PDF)

Acknowledgments

Dr. Maqsudul Alam passed away before the submission of the final version of this manuscript. Dr. Xuehua Wan accepts responsibility for the integrity and validity of the data collected and analyzed.

Author Contributions

Conceptualization: Xuehua Wan, Jennifer A. Saito, James S. Newhouse, Shaobin Hou, Maq-sudul Alam.

Data curation: Xuehua Wan, Jennifer A. Saito, James S. Newhouse, Shaobin Hou.

Formal analysis: Xuehua Wan, Jennifer A. Saito, James S. Newhouse.

Funding acquisition: Maqsdul Alam.

Investigation: Xuehua Wan, Jennifer A. Saito, James S. Newhouse, Shaobin Hou, Maqsdul Alam.

Validation: Xuehua Wan, Jennifer A. Saito.

Writing – original draft: Xuehua Wan, Jennifer A. Saito.

Writing – review & editing: Xuehua Wan, Jennifer A. Saito.

References

1. Hou S, Larsen RW, Boudko D, Riley CW, Karatan E, Zimmer M, et al. 2000. Myoglobin-like aerotaxis transducers in *Archaea* and *Bacteria*. *Nature* 403:540–544 <https://doi.org/10.1038/35000570> PMID: 10676961
2. Hou S, Freitas T, Larsen RW, Piatibratov M, Sivozhelezov V, Yamamoto A, et al. 2001. Globin-coupled sensors: a class of heme-containing sensors in *Archaea* and *Bacteria*. *Proceedings of the National Academy of Sciences of the United States of America* 98:9353–9358 <https://doi.org/10.1073/pnas.161185598> PMID: 11481493
3. Freitas TAK, Hou S, Alam M. 2003. The diversity of globin-coupled sensors. *FEBS Letters* 552: 99–104 PMID: 14527668
4. Freitas TAK, Saito JA, Wan X, Hou S, Alam M. 2008. Protoglobin and globin-coupled sensors. In: Ghosh A, ed. *The smallest biomolecules: diatomics and their interactions with heme proteins*. Amsterdam London: Elsevier, 175–202
5. Kitanishi K, Kobayashi K, Uchida T, Ishimori K, Igarashi J, Shimizu T. 2011. Identification and functional and spectral characterization of a globin-coupled histidine kinase from *Anaeromyxobacter* sp. Fw109-5. *Journal of Biological Chemistry* 286:35522–35534 <https://doi.org/10.1074/jbc.M111.274811> PMID: 21852234
6. Wan X, Tuckerman JR, Saito JA, Freitas TAK, Newhouse JS, Denery JR, et al. 2009. Globins synthesize the second messenger c-di-GMP in bacteria. *Journal of Molecular Biology* 388:262–270 <https://doi.org/10.1016/j.jmb.2009.03.015> PMID: 19285985
7. Tarnawski M, Barends TR, Schlichting I. 2015. Structural analysis of an oxygen-regulated diguanylate cyclase. *Acta Crystallographica D Biological Crystallography* 71:2158–2177 <https://doi.org/10.1107/S139900471501545X> PMID: 26527135
8. Tuckerman JR, Gonzalez G, Sousa EH, Wan X, Saito JA, Alam M, et al. 2009. An oxygen-sensing diguanylate cyclase and phosphodiesterase couple for c-di-GMP control. *Biochemistry* 48:9764–9774 <https://doi.org/10.1021/bi901409g> PMID: 19764732
9. Thijs L, Vinck E, Bolli A, Trandafir F, Wan X, Hoogewijs D, et al. 2007. Characterization of a globin-coupled oxygen sensor with a gene-regulating function. *Journal of Biological Chemistry* 282:37325–37340 <https://doi.org/10.1074/jbc.M705541200> PMID: 17925395
10. Kitanishi K, Kobayashi K, Kawamura Y, Ishigami I, Ogura T, Nakajima K, et al. 2010. Important roles of Tyr43 at the putative heme distal side in the oxygen recognition and stability of the Fe(II)-O₂ complex of YddV, a globin-coupled heme-based oxygen sensor diguanylate cyclase. *Biochemistry* 49:10381–10393 <https://doi.org/10.1021/bi100733q> PMID: 21067162
11. Römling U, Galperin MY, Gomelsky M. 2013. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. *Microbiology and Molecular Biology Reviews* 77:1–52 <https://doi.org/10.1128/MMBR.00043-12> PMID: 23471616
12. Ryan RP, Tolker-Nielsen T, Dow JM. 2012. When the PilZ don't work: effectors for cyclic di-GMP action in bacteria. *Trends in Microbiology* 20:235–242 <https://doi.org/10.1016/j.tim.2012.02.008> PMID: 22444828
13. Amikam D, Galperin MY. 2006. PilZ domain is part of the bacterial c-di-GMP binding protein. *Bioinformatics* 22:3–6 <https://doi.org/10.1093/bioinformatics/bti739> PMID: 16249258
14. Fang X, Ahmad I, Blanka A, Schottkowski M, Cimdins A, Galperin MY, et al. 2014. GIL, a new c-di-GMP-binding protein domain involved in regulation of cellulose synthesis in enterobacteria. *Molecular Microbiology* 93:439–452 <https://doi.org/10.1111/mmi.12672> PMID: 24942809

15. Tuckerman JR, Gonzalez G, Gilles-Gonzalez MA. 2011. Cyclic di-GMP activation of polynucleotide phosphorylase signal-dependent RNA processing. *Journal of Molecular Biology* 407:633–639 <https://doi.org/10.1016/j.jmb.2011.02.019> PMID: 21320509
16. Lori C, Ozaki S, Steiner S, Böhm R, Abel S, Dubey BN, et al. 2015. Cyclic di-GMP acts as a cell cycle oscillator to drive chromosome replication. *Nature* 523:236–239 <https://doi.org/10.1038/nature14473> PMID: 25945741
17. Sudarsan N, Lee ER, Weinberg Z, Moy R H, Kim JN, Link KH, et al. 2008. Riboswitches in eubacteria sense the second messenger cyclic di-GMP. *Science* 321:411–413 <https://doi.org/10.1126/science.1159519> PMID: 18635805
18. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. 2011. STING is a direct innate immune sensor of cyclic di-GMP. *Nature* 478:515–518 <https://doi.org/10.1038/nature10429> PMID: 21947006
19. Parvatiyar K, Zhang Z, Teles RM, Ouyang S, Jiang Y, Iyer SS, et al. 2012. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. *Nature Immunology* 13:1155–1161 <https://doi.org/10.1038/ni.2460> PMID: 23142775
20. Li W, Cui T, Hu L, Wang Z, Li Z, He Z-G. 2015b. Cyclic diguanylate monophosphate directly binds to human siderocalin and inhibits its antibacterial activity. *Nature Communications* 6:8330
21. Sawai H, Yoshioka S, Uchida T, Hyodo M, Hayakawa Y, Ishimori K, et al. 2010. Molecular oxygen regulates the enzymatic activity of a heme-containing diguanylate cyclase (HemDGC) for the synthesis of cyclic di-GMP. *Biochimica et Biophysica Acta* 1804:166–172 <https://doi.org/10.1016/j.bbapap.2009.09.028> PMID: 19818878
22. Wu C, Cheng YY, Yin H, Song XN, Li WW, Zhou XX, et al. 2013. Oxygen promotes biofilm formation of *Shewanella putrefaciens* CN32 through a diguanylate cyclase and an adhesin. *Scientific Reports* 3:1945 <https://doi.org/10.1038/srep01945> PMID: 23736081
23. Burns JL, Deer DD, Weinert EE. 2014. Oligomeric state affects oxygen dissociation and diguanylate cyclase activity of globin coupled sensors. *Molecular BioSystems* 10:2823–2826 <https://doi.org/10.1039/c4mb00366g> PMID: 25174604
24. Méndez-Ortiz MM, Hyodo M, Hayakawa Y, Membrillo-Hernández J. 2006. Genome-wide transcriptional profile of *Escherichia coli* in response to high levels of the second messenger 3',5'-cyclic diguanylic acid. *Journal of Biological Chemistry* 281:8090–8099 <https://doi.org/10.1074/jbc.M510701200> PMID: 16418169
25. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Molecular Biology and Evolution* 30:772–780 <https://doi.org/10.1093/molbev/mst010> PMID: 23329690
26. Li W, Cowley A, Uludag M, Gur T, McWilliam H, Squizzato S, et al. 2015a. The EMBL-EBI bioinformatics web and programmatic tools framework. *Nucleic Acids Research* 43:W580–W584
27. Brown NP, Leroy C, Sander C. 1998. MView: a web-compatible database search or multiple alignment viewer. *Bioinformatics* 14:380–381 PMID: 9632837
28. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. 2004. UCSF Chimera—a visualization system for exploratory research and analysis. *Journal of Computational Chemistry* 25:1605–1612 <https://doi.org/10.1002/jcc.20084> PMID: 15264254
29. Piatibratov M, Hou S, Brooun A, Yang J, Chen H, Alam M. (2000). Expression and fast-flow purification of a polyhistidine-tagged myoglobin-like aero- taxis transducer. *Biochim. Biophys. Acta* 1524: 149–154. PMID: 11113561
30. Simm R, Morr M, Kader A, Nitz M, Römling U. 2004. GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. *Molecular Microbiology* 53:1123–1134 <https://doi.org/10.1111/j.1365-2958.2004.04206.x> PMID: 15306016
31. Römling U, Bian Z, Hammar M, Sierralta WD, Normark S. 1998. Curli fibers are highly conserved between *Salmonella typhimurium* and *Escherichia coli* with respect to operon structure and regulation. *Journal of Bacteriology* 180:722–731 PMID: 9457880
32. Zogaj X, Nitz M, Rohde M, Bokranz W, Römling U. 2001. The multicellular morphotypes of *Salmonella typhimurium* and *Escherichia coli* produce cellulose as the second component of the extracellular matrix. *Molecular Microbiology* 39:1452–1463 PMID: 11260463
33. Kader A, Simm R, Gerstel U, Morr M, Römling U. 2006. Hierarchical involvement of various GGDEF domain proteins in rdar morphotype development of *Salmonella enterica* serovar Typhimurium. *Molecular Microbiology* 60:602–616 <https://doi.org/10.1111/j.1365-2958.2006.05123.x> PMID: 16629664
34. Cooley RB, Arp DJ, Karplus PA. 2010. Evolutionary origin of a secondary structure: π -helices as cryptic but widespread insertional variations of α -helices enhancing protein functionality. *Journal of Molecular Biology* 404:232–246 <https://doi.org/10.1016/j.jmb.2010.09.034> PMID: 20888342

35. Chan C, Paul R, Samoray D, Amiot NC, Giese B, Jenal U, et al. 2004. Structural basis of activity and allosteric control of diguanylate cyclase. *Proceedings of the National Academy of Sciences of the United States of America* 101:17084–17089 <https://doi.org/10.1073/pnas.0406134101> PMID: 15569936
36. Paul R, Abel S, Wassmann P, Beck A, Heerklotz H, Jenal U. 2007. Activation of the diguanylate cyclase PleD by phosphorylation-mediated dimerization. *Journal of Biological Chemistry* 282:29170–29177 <https://doi.org/10.1074/jbc.M704702200> PMID: 17640875
37. Kirillina O, Fetherston JD, Bobrov AG, Abney J, Perry RD. 2004. HmsP, a putative phosphodiesterase, and HmsT, a putative diguanylate cyclase, control Hms-dependent biofilm formation in *Yersinia pestis*. *Molecular Microbiology* 54:75–88 <https://doi.org/10.1111/j.1365-2958.2004.04253.x> PMID: 15458406
38. Malone JG, Williams R, Christen M, Jenal U, Spiers AJ, Rainey PB. 2007. The structure-function relationship of WspR, a *Pseudomonas fluorescens* response regulator with a GGDEF output domain. *Microbiology* 153:980–994 <https://doi.org/10.1099/mic.0.2006/002824-0> PMID: 17379708
39. Perez-Mendoza D, Coulthurst SJ, Humphris S, Campbell E, Welch M, Toth IK, et al. 2011. A multi-repeat adhesin of the phytopathogen, *Pectobacterium atrosepticum*, is secreted by a type I pathway and is subject to complex regulation involving a non-canonical diguanylate cyclase. *Molecular Microbiology* 82:719–733 <https://doi.org/10.1111/j.1365-2958.2011.07849.x> PMID: 21992096
40. Hunter JL, Severin GB, Koestler BJ, Waters CM. 2014. The *Vibrio cholerae* diguanylate cyclase VCA0965 has an AGDEF active site and synthesizes cyclic di-GMP. *BMC Microbiology* 14:22 <https://doi.org/10.1186/1471-2180-14-22> PMID: 24490592
41. Christen B, Christen M, Paul R, Schmid F, Folcher M, Jenoe P, et al. 2006. Allosteric control of cyclic di-GMP signaling. *Journal of Biological Chemistry* 281:32015–32024 <https://doi.org/10.1074/jbc.M603589200> PMID: 16923812
42. Burns JL, Rivera S, Deer DD, Joynt SC, Dvorak D, Weinert EE. 2016. Oxygen and bis(3',5')-cyclic dimeric guanosine monophosphate binding control oligomerization state equilibria of diguanylate cyclase-containing globin coupled sensors. *Biochemistry* 55:6642–6651 <https://doi.org/10.1021/acs.biochem.6b00526> PMID: 27933792
43. Pultz IS, Christen M, Kulasekara HD, Kennard A, Kulasekara B, Miller SI. 2012. The response threshold of *Salmonella* PilZ domain proteins is determined by their binding affinities for c-di-GMP. *Molecular Microbiology* 86:1424–1440 <https://doi.org/10.1111/mmi.12066> PMID: 23163901
44. Nakajima K, Kitanishi K, Kobayashi K, Kobayashi N, Igarashi J, Shimizu T. 2012. Leu65 in the heme distal side is critical for the stability of the Fe(II)-O₂ complex of YddV, a globin-coupled oxygen sensor diguanylate cyclase. *Journal of Inorganic Biochemistry* 108:163–170 <https://doi.org/10.1016/j.jinorgbio.2011.09.019> PMID: 22005448
45. Sommerfeldt N, Possling A, Becker G, Pesavento C, Tschowri N, Hengge R. 2009. Gene expression patterns and differential input into curli fimbriae regulation of all GGDEF/EAL domain proteins in *Escherichia coli*. *Microbiology* 155:1318–1331 <https://doi.org/10.1099/mic.0.024257-0> PMID: 19332833
46. Ryjenkov DA, Tarutina M, Moskvina OV, Gomelsky M. 2005. Cyclic diguanylate is a ubiquitous signaling molecule in bacteria: insights into biochemistry of the GGDEF protein domain. *Journal of Bacteriology* 187:1792–1798 <https://doi.org/10.1128/JB.187.5.1792-1798.2005> PMID: 15716451
47. Liu N, Xu Y, Hossain S, Huang N, Coursolle D, Gralnick JA, et al. 2012. Nitric oxide regulation of cyclic di-GMP synthesis and hydrolysis in *Shewanella woodii*. *Biochemistry* 51:2087–2099 <https://doi.org/10.1021/bi201753f> PMID: 22360279
48. Lahiri T, Luan B, Raleigh DP, Boon EM. 2014. A structural basis for the regulation of an H-NOX-associated cyclic-di-GMP synthase/phosphodiesterase enzyme by nitric oxide-bound H-NOX. *Biochemistry* 53:2126–2135 <https://doi.org/10.1021/bi401597m> PMID: 24628400
49. Dahlstrom KM, Giglio KM, Collins AJ, Sondermann H, O'Toole GA. 2015. Contribution of physical interactions to signaling specificity between a diguanylate cyclase and its effector. *mBio* 6:e01978–15 <https://doi.org/10.1128/mBio.01978-15> PMID: 26670387
50. Dahlstrom KM, Giglio KM, Sondermann H, O'Toole GA. 2016. The inhibitory site of a diguanylate cyclase is a necessary element for interaction and signaling with an effector protein. *Journal of Bacteriology* 198:1595–1603 <https://doi.org/10.1128/JB.00090-16> PMID: 27002135